Global N-Acetylaspartate Declines Even in Benign Multiple Sclerosis

References

1. 1.↵
   1. Isselbacher KJ,
   2. Wilson JD,
   3. Martin JB,
   4. et al.

   1. Hauser SL

   . Multiple sclerosis and other demyelinating diseases. In: Isselbacher KJ, Wilson JD, Martin JB, et al. eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 1994:2287–95
2. 2.↵
   1. Weinshenker BG

   . Natural history of multiple sclerosis. Ann Neurol 1994;36:S6–11

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Gonen O,
   2. Moriarty DM,
   3. Li BS,
   4. et al

   . Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. Radiology 2002;225:261–68

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Kurtzke JF

   . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52

   Abstract/FREE Full Text
5. 5.↵
   1. Lublin FD,
   2. Reingold SC

   . Defining the clinical course of multiple sclerosis: results of an international survey—National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11

   Abstract/FREE Full Text
6. 6.↵
   1. Ramsaransing GS,
   2. De Keyser J

   . Benign course in multiple sclerosis: a review. Acta Neurol Scand 2006;113:359–69

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Pittock SJ,
   2. McClelland RL,
   3. Mayr WT,
   4. et al

   . Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004;56:303–06

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Confavreux C,
   2. Vukusic S

   . The clinical epidemiology of multiple sclerosis. Neuroimaging Clin N Am 2008;18:589–622

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Rovaris M,
   2. Barkhof F,
   3. Calabrese M,
   4. et al

   . MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology 2009;72:1693–701

   Abstract/FREE Full Text
10. 10.↵
    1. Hawkins SA,
    2. McDonnell GV

    . Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67:148–52

    Abstract/FREE Full Text
11. 11.↵
    1. Costelloe L,
    2. Thompson A,
    3. Walsh C,
    4. et al

    . Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry 2008;79:1245–48

    Abstract/FREE Full Text
12. 12.↵
    1. Strasser-Fuchs S,
    2. Enzinger C,
    3. Ropele S,
    4. et al

    . Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox? Mult Scler 2008;14:205–11

    Abstract/FREE Full Text
13. 13.↵
    1. Ramsaransing G,
    2. Maurits N,
    3. Zwanikken C,
    4. et al

    . Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review. Mult Scler 2001;7:345–47

    Abstract/FREE Full Text
14. 14.↵
    1. Traboulsee A,
    2. Dehmeshki J,
    3. Peters KR,
    4. et al

    . Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler 2003;9:566–73

    Abstract/FREE Full Text
15. 15.↵
    1. Ceccarelli A,
    2. Rocca MA,
    3. Pagani E,
    4. et al

    . The topographical distribution of tissue injury in benign MS: a 3T multiparametric MRI study. Neuroimage 2008;39:1499–509

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Rovaris M,
    2. Riccitelli G,
    3. Judica E,
    4. et al

    . Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology 2008;71:1521–26

    Abstract/FREE Full Text
17. 17.↵
    1. Thompson AJ,
    2. Miller DH,
    3. MacManus DG,
    4. et al

    . Patterns of disease activity in multiple sclerosis. BMJ 1990;301:44–45

    FREE Full Text
18. 18.↵
    1. Brass SD,
    2. Narayanan S,
    3. Antel JP,
    4. et al

    . Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci 2004;31:225–28

    PubMedWeb of Science
19. 19.↵
    1. Audoin B,
    2. Guye M,
    3. Reuter F,
    4. et al

    . Structure of WM bundles constituting the working memory system in early multiple sclerosis: a quantitative DTI tractography study. Neuroimage 2007;36:1324–30

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Jbabdi S,
    2. Woolrich MW,
    3. Andersson JL,
    4. et al

    . A Bayesian framework for global tractography. Neuroimage 2007;37:116–29

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Matthews PM,
    2. De Stefano N,
    3. Narayanan S,
    4. et al

    . Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 1998;18:327–36

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Bjartmar C,
    2. Kidd G,
    3. Mork S,
    4. et al

    . Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893–901

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Comi G

    1. Arnold DL,
    2. De Stefano N,
    3. Narayanan S,
    4. et al

    . Axonal injury and disability in multiple sclerosis: magnetic resonance spectroscopy as a measure of dynamic pathological change in white matter. In: Comi G ed. Magnetic Resonance Spectroscopy in Multiple Sclerosis. Milan, Italy: Springer-Verlag Italia; 2001:61–67
24. 24.↵
    1. Dutta R,
    2. Trapp BD

    . Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68:S22–31, discussion S43–54

    Abstract/FREE Full Text
25. 25.↵
    1. Benarroch EE

    . N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology 2008;70:1353–57

    FREE Full Text
26. 26.↵
    1. Mainero C,
    2. De Stefano N,
    3. Iannucci G,
    4. et al

    . Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 2001;56:1331–34

    Abstract/FREE Full Text
27. 27.↵
    1. Mathiesen HK,
    2. Jonsson A,
    3. Tscherning T,
    4. et al

    . Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol 2006;63:533–36

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Enzinger C,
    2. Ropele S,
    3. Strasser-Fuchs S,
    4. et al

    . Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol 2003;60:65–70

    PubMedWeb of Science
29. 29.↵
    1. Miller DH,
    2. Thompson AJ,
    3. Filippi M

    . Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 2003;250:1407–19

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Filippi M,
    2. Bozzali M,
    3. Rovaris M,
    4. et al

    . Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433–37

    Abstract/FREE Full Text
31. 31.↵
    1. Inglese M,
    2. Ge Y,
    3. Filippi M,
    4. et al

    . Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004;21:1825–29

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Sayao AL,
    2. Devonshire V,
    3. Tremlett H

    . Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 2007;68:496–500

    Abstract/FREE Full Text
33. 33.↵
    1. Trapp BD,
    2. Peterson J,
    3. Ransohoff RM,
    4. et al

    . Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–85

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Rovaris M,
    2. Filippi M,
    3. Calori G,
    4. et al

    . Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol 1997;244:266–70

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Smith SM,
    2. Zhang Y,
    3. Jenkinson M,
    4. et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Gonen O,
    2. Viswanathan AK,
    3. Catalaa I,
    4. et al

    . Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998;40:684–89

    PubMedWeb of Science
37. 37.↵
    1. Benedetti B,
    2. Rigotti DJ,
    3. Liu S,
    4. et al

    . Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths. AJNR Am J Neuroradiol 2007;28:72–75

    Abstract/FREE Full Text
38. 38.↵
    1. Li DK,
    2. Held U,
    3. Petkau J,
    4. et al

    . MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006;66:1384–89

    Abstract/FREE Full Text
39. 39.↵
    1. Gonen O,
    2. Oberndorfer TA,
    3. Inglese M,
    4. et al

    . Reproducibility of three whole-brain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2007;28:267–71

    Abstract/FREE Full Text
40. 40.↵
    1. Benedetti B,
    2. Rovaris M,
    3. Rocca M,
    4. et al

    . In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler 2009;15:789–94. Epub 2009 May 22

    Abstract/FREE Full Text
41. 41.↵
    1. Chard DT,
    2. Griffin CM,
    3. McLean MA,
    4. et al

    . Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:2342–52

    Abstract/FREE Full Text
42. 42.↵
    1. De Stefano N,
    2. Narayanan S,
    3. Francis GS,
    4. et al

    . Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65–70

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Pelletier J,
    2. Audoin B,
    3. Reuter F,
    4. et al

    . Plasticity in MS: from functional imaging to rehabilitation. Int MS J 2009;16:26–31

    PubMed
44. 44.↵
    1. Gonen O,
    2. Catalaa I,
    3. Babb JS,
    4. et al

    . Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000;54:15–19

    Abstract/FREE Full Text
45. 45.↵
    1. Weinshenker BG,
    2. Bass B,
    3. Rice GP,
    4. et al

    . The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(pt 6):1419–28

    Abstract/FREE Full Text